hyperthyroidism and tirzepatide Dual Glucagon-Like Peptide-1 (GLP-1) Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonist-Associated Thyroiditis: A Case Report of Thyroid Dysfunction Following Use The Thyroid Twist: How GLP-1

Limitations This consensus statement has several noteworthy limitations

This feature enhances the overall experience for users looking for consistent assistance in their weight management journey

The study found that treatment with Tesofensine led to greater weight reduction compared to placebo, with mean weight loss percentages of 4.5%, 9.2%, and 10.6% higher for the 0.25 mg, 0.5 mg, and 1.0 mg doses, respectively

This type of pattern makes a potential link more compelling than a single, static finding and provides a significant signal that warrants serious follow-up investigation. However, Vavvas did point out that the study has some limitations

In no way, the Honorary Editor-in-Chief, Editorial Board Members, the Indian Society of Gastroenterology, printer/publishers, or are responsible for the results/findings and content of this article

Median follow-up was 4 years